Screener
BioMarin Pharmaceuticals BMRN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other assets | 9,005 | (13,505) |
| Accounts payable and accrued liabilities | 26,265 | 3,111 |
| Other long-term liabilities | 6,667 | 5,537 |
| Net cash provided by operating activities | 388,760 | 359,665 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property, plant and equipment | (49,739) | (33,869) |
| Maturities and sales of investments | 767,277 | 195,738 |
| Purchases of investments | (25,792) | (202,433) |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's operating cash flow?
- BioMarin Pharmaceuticals (BMRN) reported operating cash flow of $168.11M in Q2 2026.
- How has BioMarin Pharmaceuticals's operating cash flow changed year-over-year?
- BioMarin Pharmaceuticals's operating cash flow decreased by 9.3% year-over-year, from $185.27M to $168.11M.
- What is the long-term trend for BioMarin Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's operating cash flow has grown at a 28.4% compound annual growth rate (CAGR), from $304.54M to $827.99M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about BioMarin Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude